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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
glycaemic carbohydrates and contribution to normal cognitive function 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Dextro Energy GmbH & Co. KG, submitted for the authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to glycaemic carbohydrates and contribution to normal cognitive function. 
The scope of the application was proposed to fall under a health claim based on newly developed scientific 
evidence. The Panel considers that the food constituent, glycaemic carbohydrates, which is the subject of the 
health claim, is sufficiently characterised in relation to the claimed effect. Contribution to normal cognitive 
function is a beneficial physiological effect. Glycaemic carbohydrates contribute to the maintenance of normal 
brain functions, including cognition. The Panel concludes that a cause and effect relationship has been 
established between the consumption of glycaemic carbohydrates and contribution to normal cognitive function. 
A daily intake of 130 g of glycaemic carbohydrates has been estimated to cover the glucose requirement of the 
brain. Such amounts can be consumed as part of a balanced diet. The target population is the general population. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Dextro Energy GmbH & Co. KG, submitted for the authorisation of a 
health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority 
of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to 
deliver an opinion on the scientific substantiation of a health claim related to glycaemic carbohydrates 
and contribution to normal cognitive function. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The applicant proposed “glucose” as the food constituent that is the subject of the health claim. From 
the information provided by the applicant, the Panel considers that the food constituent that is the 
subject of the health claim is glycaemic carbohydrates, which are dietary sources of glucose. The 
Panel considers that glycaemic carbohydrates are sufficiently characterised in relation to the claimed 
effect.  
The claimed effect proposed by the applicant is “contributes to normal cognitive function”. The target 
population proposed by the applicant is the general population. The Panel considers that contribution 
to normal cognitive function is a beneficial physiological effect.  
Glycaemic carbohydrates contribute to the maintenance of normal brain functions, including 
cognition.  
The Panel concludes that a cause and effect relationship has been established between the 
consumption of glycaemic carbohydrates and contribution to normal cognitive function.  
A daily intake of 130 g of glycaemic carbohydrates has been estimated to cover the glucose 
requirement of the brain. Such amounts can be consumed as part of a balanced diet. The target 
population is the general population. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 01/08/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence.  
 On 10/09/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 10/11/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 27/11/2014. 
 During its meeting on 06/02/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to  glycaemic 
carbohydrates and contribution to normal cognitive function. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: glycaemic carbohydrates and 
contribution to normal cognitive function. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of glycaemic carbohydrates, a positive assessment of its safety, nor a decision on whether 
glycaemic carbohydrates are, or are not, classified as foodstuffs. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Dextro Energy GmbH & Co. KG. Hafenstrasse 77, 47809, Krefeld, 
Germany. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent that is the subject of the health claim is glucose 
(synonymous dextrose), C6H12O6, M=180.16 g/mol. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is normal cognitive function. For the human body, 
energy is available in the form of the cellular energy-carrying molecule such as adenosine 
triphosphate, most of which is generated through aerobic cellular respiration of carbohydrate such as 
glucose. Thus, glucose is the preferred energy source for most body cells including the brain which 
requires glucose for its energy needs, it consumes 20 % of the energy provided by the diet. Glucose is 
ingested in form of monosaccharides or in form of di- oligo- and polysaccharides, mainly starch, 
which has to be broken down into its constituent monosaccharide glucose before absorption. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “glucose contributes to 
normal cognitive function”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is the general population. 
According to the applicant, a total intake of 130 g of dietary glycaemic carbohydrates (e.g. glucose) 
per day, for both children (>1 year) and adults, is estimated to cover the whole glucose requirement of 
the brain and its general function. According to the applicant, lower amounts of glucose which do not 
cover the total glucose requirements of the brain nevertheless contribute to its normal function and to 
unique cognitive processes. Ingestion of a significant amount of carbohydrates might be defined as 
15 % (about 20 g) of the daily dose of 130 g carbohydrates needed for normal brain function. 
Analogous to the condition of use for vitamins and minerals 15 % should also be seen as significant 
and defined as the condition of use of the claim for glucose and normal cognitive function. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The applicant proposed “glucose” as the food constituent that is the subject of the health claim.  
Glucose is one of the main glycaemic carbohydrates in the diet. Glycaemic carbohydrates can be 
classified, according to their degree of polymerisation, as simple (monosaccharides and disaccharides) 
or complex (oligosaccharides and polysaccharides). Glycaemic carbohydrates are digested and 
absorbed in the human small intestine, and provide glucose to body cells as a source of energy (EFSA 
NDA Panel, 2010).  
From the information provided by the applicant, the Panel considers that the food constituent that is 
the subject of the health claim is glycaemic carbohydrates, which are dietary sources of glucose.  
Glycaemic carbohydrates and contribution to normal cognitive function  
 
 
EFSA Journal 2015;13(2):4027 6 
The Panel considers that the food constituent, glycaemic carbohydrates, which is the subject of the 
health claim, is sufficiently characterised in relation to the claimed effect.  
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “contributes to normal cognitive function”. The target 
population proposed by the applicant is the general population. 
Cognitive function encompasses several domains, including memory, attention, alertness, learning, 
intelligence, language and problem solving, which are well-defined psychological constructs.  
The Panel considers that contribution to normal cognitive function is a beneficial physiological effect.  
3. Scientific substantiation of the claimed effect 
Glycaemic carbohydrates are the main source of energy in most human diets. Glucose is the preferred 
energy source for most body cells. The brain requires glucose for its energy needs. An intake of 130 g 
of dietary glycaemic carbohydrates per day, for both children (>1 year) and adults, is estimated to 
cover the glucose requirement of the brain (IoM, 2005; EFSA NDA Panel, 2010). 
Glycaemic carbohydrates contribute to the maintenance of normal brain functions (EFSA NDA Panel, 
2011), including cognition.  
The Panel concludes that a cause and effect relationship has been established between the 
consumption of glycaemic carbohydrates and contribution to normal cognitive function.  
The Panel considers that the conditions of use for the claim on glycaemic carbohydrates and 
maintenance of normal brain function, which was assessed by the Panel with a favourable outcome, 
also apply to this claim on glycaemic carbohydrates and contribution to normal cognitive function 
(EFSA NDA Panel, 2011). 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “glycaemic 
carbohydrates contribute to normal cognitive function”. 
5. Conditions and restrictions of use  
A daily intake of 130 g of glycaemic carbohydrates has been estimated to cover the glucose 
requirement of the brain. Such amounts can be consumed as part of a balanced diet. The target 
population is the general population. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, glycaemic carbohydrates, which is the subject of the health claim, is 
sufficiently characterised in relation to the claimed effect. 
 The claimed effect proposed by the applicant is “contributes to normal cognitive function”. 
The target population proposed by the applicant is the general population. Contribution to 
normal cognitive function is a beneficial physiological effect. 
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 A cause and effect relationship has been established between the consumption of glycaemic 
carbohydrates and contribution to normal cognitive function. 
 The following wording reflects the scientific evidence: “glycaemic carbohydrates contribute 
to normal cognitive function”. 
 A daily intake of 130 g of glycaemic carbohydrates has been estimated to cover the glucose 
requirement of the brain. Such amounts can be consumed as part of a balanced diet. The 
target population is the general population. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on glycaemic carbohydrates and contribution to normal cognitive 
function pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No 0421_DE). 
August 2014. Submitted by Dextro Energy GmbH & Co. KG. 
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